Register

Contact us

Home Fangda represented Quan Capital in its equity investment in the Zenas USD 200 mln series C financing led by SR One, NEA, Norwest Venture Partners and Delos Capital

The press releases published in this section have been uploaded by law firms. Their content has not been appraised or edited by Law.asia, and no responsibility is taken for the accuracy of the information they contain or any misrepresentation therein. For our independent editorial content, please visit our homepage.

Fangda represented Quan Capital in its equity investment in the Zenas USD 200 mln series C financing led by SR One, NEA, Norwest Venture Partners and Delos Capital

: Description
: Law Firm

Fangda Partners represented Quan Capital as an existing investor in its equity investment in the Zenas series C financing led by SR One, NEA, Norwest Venture Partners and Delos Capital, with a total transaction value of 200 mln USD. The transaction announced on May 8, 2024. The Fangda team on this deal was led by partner Samuel Xie. Fangda handled advice on documents review, revise and negotiation. Zenas is a global biopharmaceutical company committed to becoming leader in the development and commercialization of inflammation and immunology-directed therapies.
Law Firms
- Fangda Partners